REGULATORY · COMPETITIVE · INDIA
Government raises ceiling prices for NLEM medicines by 0.6%
Change
The National Pharmaceutical Pricing Authority authorized a 0.6% increase in ceiling prices for more than 1,000 drugs on the National List of Essential Medicines effective April 1.
Why it matters
The NPPA adjusted prices based on the Wholesale Price Index annual change (0.64956%) and authorized a 0.6% upward revision. The adjustment covers more than 1,000 medicines on the National List of Essential Medicines, including painkillers, antibiotics, anti-anaemia drugs, vitamins, steroids and some COVID-19 treatments. The new ceilings take effect on April 1. An industry executive stated that API and solvent costs have risen substantially due to the Iran war and that the marginal increase will hardly offset those input-cost rises.
Implications
- · Regulated maximum selling prices for listed medicines increase 0.6%, directly raising allowable revenues per unit for manufacturers, distributors, and pharmacies.
- · The marginal permitted increase limits the scope for offsetting substantially higher API and solvent input costs, sustaining pressure on sector margins as stated by an industry executive.
- · Price-control compliance and pricing updates will be required across manufacturing, distribution, and retail systems to reflect the new ceilings.
Who is affected
- · Manufacturers
- · Compliance teams
What to watch
- · Effective April 1
Source
Topics
Law & Public Safety Regulatory Actions Health & Medicine Pharma & Biotech